Skyline Healthcare

Skyline Therapeutics is a clinical-stage gene therapy company dedicated to the discovery and development of innovative adeno-associated virus (AAV) therapies for rare and severe diseases. The company utilizes its proprietary capDRIVE platform for novel AAV capsid discovery and vector engineering to optimize tissue tropism and transduction efficiency. Its lead clinical program, SKG0106, is a one-time intravitreal gene therapy for neovascular age-related macular degeneration (nAMD) that has demonstrated promising safety and efficacy in early trials. Skyline maintains a robust pipeline across ophthalmology, neurology, and metabolic therapeutic areas, supported by fully integrated GMP manufacturing capabilities.